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Survival Association of Angiotensin Inhibitors in Heart Failure
With Reduced Ejection Fraction: Comparisons Using SelfIdentified Race and Genomic Ancestry
JASMINE A. LUZUM, Pharmd, PhD,1,2 OZIOMA EDOKOBI, BS,1 MICHAEL P. DORSCH, Pharmd,1 EDWARD PETERSON, PhD,3
BIN LIU, MPH, PhD,3 HONGSHENG GUI, PhD,2 L. KEOKI WILLIAMS, MD, MPH,2,4 AND DAVID E. LANFEAR, MD, MS2,5
Ann Arbor, and Detroit, Michigan

ABSTRACT
Background: It remains unclear whether there is a racial disparity in the response to angiotensin inhibitors
in patients with heart failure with reduced ejection fraction (HFrEF) and whether the role of genomic ancestry plays a part. Therefore, we compared survival rates associated with angiotensin inhibitors in patients
with HFrEF by self-identified race and proportion of West African genomic ancestry.
Methods: Three datasets totaling 1153 and 1480 self-identified Black and White patients, respectively,
with HFrEF were meta-analyzed (random effects model) for race-based analyses. One dataset had genomic
data for ancestry analyses (416 and 369 self-identified Black and White patients, respectively). Cox proportional hazards regression, adjusted for propensity scores, assessed the association of angiotensin inhibitor
exposure with all-cause mortality by self-identified race or proportion of West African genomic ancestry.
Results: In meta-analysis of self-identified race, adjusted hazard ratios (95% CI) for exposure to angiotensin inhibitors were similar in self-identified Black and White patients with HFrEF: 0.52 (0.31 0.85)
P = 0.006 and 0.54 (0.42 0.71) P = 0.001, respectively. Results were similar when the proportion of West
African genomic ancestry was > 80% or < 5%: 0.66 (0.34 1.25) P = 0.200 and 0.56 (0.26 1.23)
P = 0.147, respectively.
Conclusions: Among self-identified Black and White patients with HFrEF, reduction in all-cause mortality associated with exposure to angiotensin inhibitors was similar regardless of self-identified race or proportion of West African genomic ancestry. (J Cardiac Fail 2021;00:1 11)
Key Words: Race, ancestry, Heart failure, Angiotensin converting enzyme inhibitors, Angiotensin receptor blockers, Survival, Disparity.

contribute to health care disparities,2,3 differences in drug
response could also contribute to poorer outcomes in Black
Americans with HF. The landmark clinical trials of angiotensin inhibitors, which included angiotensin-converting enzyme
inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and
angiotensin receptor-neprilysin inhibitors (ARNIs), enrolled
few Black patients with HF and reduced ejection fraction
(HFrEF); the number ranged from 1% to 17% of participants.4 10 Thus definitive evidence for the efficacy of angiotensin inhibitors in Black Americans with HFrEF is limited.
Post hoc analyses of some of the landmark trials of angiotensin inhibitors in patients with HFrEF suggest a racial disparity in drug responses.7,11,12 Neither the subgroup nor the
meta-analyses of the landmark trials found a statistically
significant benefit for angiotensin inhibitors in Black
patients with HFrEF.7,12,13 One study even found a statistically significant treatment-by-race interaction, in which
Black patients received significantly less benefit from an
ACEI in regard to HF hospitalizations compared to White
patients.12 These findings are concerning because it is well
known that a significant racial disparity exists in the

Introduction
Black Americans are disproportionately burdened by
heart failure (HF). The relative incidence of HF is 50%
higher in Black Americans, and they present with HF at significantly younger ages, Black Americans also have significantly higher rates of both hospitalizations and mortality
due to HF.1 Although racism and socioeconomic disparities
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response to angiotensin inhibitors in the treatment of hypertension.14 Thus, angiotensin inhibitors are not recommended as a first-line therapy for Black patients with
hypertension (in the absence of chronic kidney disease).14
Angiotensin inhibitors are still recommended as a first-line
therapy in patients with HFrEF regardless of race,15 but the
racial disparity in hypertension has led to doubts about the
efficacy of angiotensin inhibitors in Black patients with
HFrEF.16
Whether the significant racial disparity in the response to
angiotensin inhibitors for the treatment of hypertension also
exists for the treatment of HFrEF has been strongly
debated.11,16 20 A major limitation of the previous studies
of this potential disparity in patients with HFrEF was the
reliance on self-identified race. Race is a social, not a scientific construct.2 Thus, using race alone may convolute
genetic, social and environmental contributions to drug outcomes. Analyzing drug outcomes according to biogeographic ancestry may help to parse the genomic component
from other, nongenomic factors.21--24 This may be particularly important for Black Americans, who can have substantial differences in the proportion of African ancestry due to
admixture.25,26 Therefore, for the first time, this study compared long-term survival benefit resulting from angiotensin
inhibitors by both self-identified race and genomic ancestry
in patients with HFrEF.

Methods
Patient Data

Three datasets were used to compare the survival benefit
of angiotensin inhibitors between self-identified Black and
White race: (1) patients with HFrEF enrolled in the Henry
Ford HF Pharmacogenomic Registry (HFGR) at Henry
Ford Health System (HFHS) in Detroit, MI27; (2) a retrospective analysis of electronic health records (EHR) and
insurance claims data of patients with HFrEF at HFHS
(who were not enrolled in the HFGR) (HFHS-EHR); and
(3) data from the Guiding Evidence-Based Therapy Using
Biomarker Intensified Treatment in Heart Failure (GUIDEIT) trial.28 Only the HFGR had genomic data available, so
it was the only dataset available for ancestry analyses.
Patients with HF were enrolled into the prospective
HFGR between October 2007 and March 2015. The methods of this HF registry have been published previously.27
Briefly, patients were enrolled if they were 18 years of age
of older, insured by the HFHS-affiliated plan (Health Alliance Plan [HAP]) and met the definition of HF as defined
by the Framingham Heart Study.29 Only patients insured by
HAP were included because that allowed access to their
pharmacy claims data. Unlike medication data from the
EHR, which provides only the drugs the patients have been
prescribed, pharmacy claims provide additional information
regarding medication adherence, such as whether the
patient picked up a prescription from the pharmacy, when

the patient picked up the prescription and how many tablets/capsules were dispensed. Patients were excluded if they
were dependent on supplemental oxygen or dialysis.
Patients on supplemental oxygen were excluded because
that could signify severe chronic obstructive pulmonary disease. If patients had chronic obstructive pulmonary disease
but did not require supplemental oxygen, they could be
enrolled. Detailed phenotypic information (eg, demographics, physical examination, medical history, laboratory
values, functional status, medications) were collected upon
enrollment. Records of patients’ deaths were collected from
the Social Security Administration Death Master File,
National Death Index, Michigan State Division of Vital
Records, and the Henry Ford Health System administrative
data, through December 31, 2018. Blood samples were collected at enrollment into the HFGR and were immediately
processed and stored at –70˚C. Each sample was genotyped
using the Axiom Biobank array (Affymetrix; ThermoFisher
Scientific, Cambridge, MA), which includes the following
»600K genetic variants: (1) »300K genome-wide variants
with minor allele frequencies > 1%; (2) »250K low-frequency (< 1%) coding variants from global exome
sequencing projects; and (3) an additional »50K variants to
improve West African ancestry coverage (Yoruba in Ibadan, Nigeria [YRI] booster). The proportion of West African genetic ancestry was estimated for each patient using
ANCESTRYMAP2.0.30 Briefly, the software program uses
a Hidden Markov Model to combine data across unlinked
single nucleotide polymorphisms and incorporates information from many neighboring markers to infer ancestry. All
patients enrolled into the HFGR were eligible for the current study, except for the patients with HF with preserved
ejection fraction (HFpEF) enrolled in the HFGR. Only
patients with left ventricular ejection fraction (LVEF) 
40%, verified by echocardiography, nuclear stress tests or
radionuclide blood pool imaging, were included in this
analysis.
The HFHS-EHR dataset is a retrospective analysis of
HFHS EHR and insurance claims data. This dataset is more
recent than the HFGR because the data were collected from
January 1, 2014 to December 31, 2018. Data for all patients
at HFHS within that time period who were diagnosed with
HF in the inpatient setting or in at least 2 outpatient visits
were collected. Patients who were already enrolled in the
HFGR were excluded from the HFHS-EHR cohort. Only
patients that were HAP members and those with a documented LVEF  40% were included in this analysis. Information concerning patients’ deaths was collected from the
Michigan State Division of Vital Records through December 31, 2018.
Detailed methods from GUIDE-IT have been previously
published.28 Briefly, GUIDE-IT was a multicenter, randomized controlled trial (RCT) conducted between January
2013 and September 2016 at 45 sites in the United States
and Canada. The study planned to randomize 1100 patients
with HFrEF (ejection fraction  40%), elevated natriuretic
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peptide levels within the prior 30 days and histories of prior
HF events (HF hospitalization or equivalent) to either an
NT-proBNP guided strategy or usual care. However,
enrollment was stopped prematurely at 894 patients because
of futility. The primary endpoint was the composite of timeto-first HF hospitalization or cardiovascular mortality. Prespecified secondary endpoints included all-cause mortality,
total hospitalizations for HF, days alive and not hospitalized
for cardiovascular reasons, the individual components of
the primary end point, and adverse events. The intervention
did not significantly affect the any of the endpoints. Only
patients with Black or White race were included in this
analysis, and only all-cause mortality was used as the outcome. The insurance status of the patients in GUIDE-IT
was not available.
Calculation of Angiotensin Inhibitor Exposure

Time-varying drug exposure was calculated using pharmacy claims data in the HFHS datasets as previously
described.31 We demonstrated that this approach is superior
to the typical use of a single time point and dichotomous
classification of drug exposure (eg, discharge medication
status) for association with clinical outcomes.32 Briefly,
doses of angiotensin inhibitors were standardized into dose
equivalents by the percentage of the target dose used in
HFrEF clinical trials, or for angiotensin inhibitors not tested
in HFrEF clinical trials, by the maximum daily dose (Supplementary Table 1). Exposure was calculated by multiplying the standardized dose equivalent by the quantity of
medication dispensed in a 6-month time block, divided by
the total number of days in the 6-month time block. This
was calculated for each patient for each day of observation,
so this method accounts for both dose and adherence over a
rolling period of time (6 months). For example, the total
daily target dose of candesartan is 32 mg. If a patient were
prescribed 16 mg of candesartan daily, and had picked up
the prescription from the pharmacy so that there was continuous availability over the previous 6 months, then the calculated angiotensin inhibitor exposure would be 0.5. Exposure
was calculated for every day over the course of follow-up in
the HFGR and HFHS-EHR datasets. The data from the
GUIDE-IT trial did not include pharmacy claims, so exposure was calculated based on the medication data collected
at each study visit over the course of follow-up: at baseline,
2 weeks, 6 weeks, and every 3 months through 24 months.
Statistical Analysis

The overall analytic approach used Cox proportional
hazards regression models to test the association of timevarying angiotensin inhibitor exposure with all-cause mortality by self-identified race or proportion of West African
genomic ancestry. For the continuous variables, a normal
distribution was determined by the Kolmogorov-Smirnov
test and visual inspection of distribution plots. Continuous
baseline variables were summarized by the median (interquartile range) and compared by self-identified race or

proportion of West African ancestry (> 80% vs < 5%) by
the Mann-Whitney U test. The proportion of West African
ancestry in Black and White Americans is a continuous distribution, and we and others have shown that there is more
genomic admixture in Black Americans than in White
Americans.27,33 Therefore, the cutoffs of > 80% and < 5%
of West African ancestry were chosen in order to compare
the extremes of the ancestry distributions, while still maintaining comparable sample sizes in the groups with high
and low West African ancestry. Categorical baseline variables were summarized by counts and percentages and compared by using x2 tests or Fisher exact tests when
appropriate. Angiotensin inhibitor exposure was modeled
as a continuous variable with values ranging from 0 to 1.
Exposure was modeled as a time-varying continuous variable, so the hazard ratios for the association between angiotensin inhibitor exposure and all-cause mortality were
scaled as 0 exposure vs target exposure.15 Average exposure over time was dichotomized only when plotting survival curves (high exposure was defined as the 3rd quartile
of average angiotensin exposure over the course of followup, and low exposure was defined as the 1st quartile). Two
separate sets of models were made, 1 for self-identified race
(dichotomous variable) and another for West African ancestry (continuous variable); that is, both factors were not in
models together. The models were otherwise similar (ie,
had the same covariates and endpoints). Interaction between
either self-identified race or proportion of West African
ancestry and angiotensin inhibitor exposure was tested by
incorporating a multiplicative interaction term within the
models for time to all-cause mortality (eg, self-identified
race*angiotensin inhibitor exposure). Models stratified by
self-identified race and West African ancestry > 80% and
< 5% were also developed. For the datasets from the Henry
Ford Health System (HFGR and HFHS-EHR), the time
dependency of angiotensin inhibitor exposure varied by
each day of follow-up in the Cox proportional hazards models. For GUIDE-IT, the time dependency of exposure varied
at each follow-up visit when medication data were collected. Patients were not randomized to treatment by angiotensin inhibitors, so the models were adjusted for a
propensity score based on the use of angiotensin inhibitors.
The propensity score was calculated by using logistic
regression of all baseline characteristics in Table 1 (ie, not
length of follow-up or death data), and the output was separated into quartiles and used as an ordinal adjuster in the
Cox regression models.34 The logistic model for the propensity score used a binary outcome of angiotensin inhibitor
exposure (yes/no) at baseline. In addition to using the propensity score as a covariate, propensity matching was also
performed, and analyses were repeated in propensitymatched subgroups. Results of the 3 datasets with self-identified race were meta-analyzed using a random effects
model. Survival curves were generated from the adjusted
Cox proportional hazards models with time-varying angiotensin inhibitor exposure. That approach was used instead
of Kaplan-Meier plots because Kaplan-Meier plots use only
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HFGR

GUIDE-IT

Black
n = 416 (53%)

White
n = 369 (47%)

Pa

Black
n = 415 (40%)

White
n = 623 (60%)

Pa

Black
n = 322 (40%)

White
n = 488 (60%)

Pa

155 (37%)
63 (56–73)
30 (20–35)
149 (36%)
383 (92%)
84 (20%)
118 (28%)
81 (19%)
55 (13%)
182 (44%)
29 (26–35)
128 (112–143)
72 (63-82)
226 (25–579)
1.15 (0.90–1.58)
19 (14–24)
5 (0–37)
266 (64%)
1414 (860–1996)
109 (26%)

113 (31%)
72 (63–80)
33 (25–37)
214 (58%)
307 (83%)
88 (24%)
69 (19%)
143 (39%)
44 (12%)
141 (38%)
29 (25–34)
122 (109–138)
69 (62–77)
278 (129–558)
1.09 (0.89–1.40)
20 (15–25)
3 (0–19)
204 (55%)
1436 (840–2028)
96 (26%)

0.050
<.001
<.001
<.001
<.001
0.217
0.002
<.001
0.585
0.116
0.428
0.015
0.001
0.069
0.008
0.002
0.011
0.014
0.898
0.953

180 (43%)
65 (55–77)
30 (24–35)
165 (40%)
351 (85%)
144 (35%)
39 (9%)
77 (19%)
93 (22%)
180 (43%)
29 (24–34)
126 (112–140)
82 (72–94)
594 (221–1220)
1.17 (0.93–1.47)
23 (17–28)
1 (0–20)
219 (53%)
760 (345–1264)
116 (28%)

211 (34%)
74 (63–83)
30 (24–36)
358 (58%)
486 (78%)
251 (40%)
38 (6%)
238 (38%)
154 (25%)
260 (42%)
28 (24–33)
120 (107–132)
76 (65–90)
563 (263–1280)
1.10 (0.89–1.41)
26 (21–30)
0 (0–16)
328 (53%)
637 (275–1126)
228 (37%)

0.002
<.001
0.520
<.001
0.009
0.069
0.047
<.001
0.392
0.601
0.080
<.001
<.001
0.761
0.008
<.001
0.164
0.969
0.008
0.004

127 (39%)
57 (50–65)
20 (15–30)
117 (36%)
281 (87%)
73 (23%)
130 (40%)
98 (30%)
34 (11%)
149 (46%)
30 (26–37)
118 (105–136)
80 (69-90)
241 (135–503)
1.35 (1.10–1.80)
21 (17–25)
25 (6–50)
302 (94%)
497 (258–726)
37 (11%)

128 (26%)
66 (58–75)
25 (20–30)
291 (60%)
364 (75%)
108 (22%)
176 (36%)
229 (47%)
54 (11%)
223 (46%)
28 (24–32)
110 (100–123)
74 (66–83)
352 (197–682)
1.27 (1.01–1.70)
23 (18–28)
25 (6–50)
461 (95%)
442 (197–725)
91 (19%)

<.001
<.001
<.001
<.001
<.001
0.869
0.224
<.001
0.813
0.872
<.001
<.001
<.001
<.001
0.062
<.001
0.127
0.861
0.042
0.006

COPD, chronic obstructive pulmonary disease; EHR, electronic health record; exp., exposure (% of HFrEF target dose or maximum dose); GUIDE-IT, Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure trial;28 HFHS, Henry Ford Health System; HR, heart rate; LVEF, left ventricular ejection fraction; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure risk score;27 NT
pro-BNP, N-terminal pro b-type natriuretic peptide; SBP, systolic blood pressure.
NOTES. ap values are for the comparison between self-identified Black vs White race within each dataset. All of the p-values < 0.05 in the table need to be made boldface.
b
MAGGIC risk score was calculated without angiotensin inhibitors as input variables.
c
Angiotensin inhibitor exposure at baseline was the percentage of the target dose used in HFrEF clinical trials, or the angiotensin inhibitors not tested in HFrEF clinical trials, the percentage of the maximum daily
dose used by the patient at study entry. (See Supplementary Table 1 for standardized dose equivalents.)

ARTICLE IN PRESS

Female
Age (years)
LVEF (%)
Ischemic etiology
Hypertension
COPD
Chronic kidney disease
Atrial fibrillation
Stroke
Diabetes
Body mass index (kg/m2)
SBP (mmHg)
HR (bpm)
NT pro-BNP (pg/mL)
BNP (pg/mL)
Serum creatinine (mg/dL)
b
MAGGIC risk score
c
Angiotensin inhibitor exp.
Beta-blocker treatment
Length of follow-up (days)
Deaths

HFHS-EHR
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the values of variables at baseline, and they would not allow
angiotensin inhibitor exposure to vary over time. For main
effects, P < 0.05 was considered statistically significant,
and for interactions, P < 0.1 was considered statistically
significant. All analyses were performed using SAS version
9.4 (SAS Institute, Cary, NC).
Results
Baseline Characteristics by Self-identified Race and
West African Ancestry

Table 1 compares baseline characteristics between the
self-identified Black and White patients within the 3 datasets used to compare self-identified race: HFGR (n = 416
Black and n = 369 White); HFHS-EHR (n = 415 Black and
623 White); and GUIDE-IT (n = 322 Black and 488 White).
The self-identified Black and White patients differed significantly in many ways, such as self-identified Black patients
were consistently more female, younger, had lower LVEF,
less ischemic etiology, and more hypertension. The mean
angiotensin inhibitor exposure at baseline (expressed as %
of HFrEF target dose or, in the absence of an established
HFrEF dose, the maximum dose) was consistently higher in
the self-identified Black patients than in the White patients.
The difference was statistically significant in the HFGR
(21% § 29% and 14% § 22% in Black and White patients,
respectively; P < 0.011). The HFGR had the longest mean

follow-up, nearly 1500 days, and the GUIDE-IT trial had
the shortest mean follow-up, approximately 450 days. Follow-up was significantly longer in the Black patients in
both the HFHS-EHR and GUIDE-IT datasets, which is
probably due to the significantly lower mortality rate for
self-identified Black patients in those datasets: 28% vs 37%
for Black and White patients in HFHS-EHR (P = 0.004)
and 11% vs 19% (P = 0.006) in GUIDE-IT.
Table 2 summarizes the characteristics of the HFGR stratified by self-identified race and by West African ancestry.
Although 416 and 369 patients self-identified their race as
Black and White, respectively, only 309 and 353 patients
had > 80% and < 5% West African ancestry, respectively.
The mean proportion of West African ancestry in the selfidentified Black and White patients was 85% § 19% and
0.9% § 5.6% (P < 0.001), respectively. The significant differences between self-identified Black and White race, such
as sex, age, LVEF, comorbidities, etc., were also significantly
different when compared by > 80% and < 5% West African
ancestry.

Association of Angiotensin Inhibitor Exposure With
Survival by Self-identified Race

Fig. 1 shows the adjusted association of time-varying angiotensin inhibitor exposure with all-cause mortality in the Cox
proportional hazards models in the 3 datasets and the meta-

Table 2. Baseline Characteristics and Outcomes of the HFGR Stratified by Self-Identified Race and West African Ancestry.
Self-identified Race
Characteristic

Black
n = 416 (53%)

White
n = 369 (47%)

Female
Age (years)
Left ventricular ejection fraction (%)
Ischemic etiology
Hypertension
Chronic obstructive pulmonary disease
Chronic kidney disease
Atrial fibrillation
Stroke
Diabetes
Body mass index (kg/m2)
Systolic blood pressure (mmHg)
Heart rate (beats per minute)
NT pro-BNP (pg/mL)
Serum creatinine (mg/dL)
b
MAGGIC risk score
c
Angiotensin inhibitor exposure
Beta-blocker treatment
Proportion West African ancestry
Length of follow-up (days)
Deaths

155 (37%)
63 (56–73)
30 (20–35)
149 (36%)
383 (92%)
84 (20%)
118 (28%)
81 (19%)
55 (13%)
182 (44%)
29 (26–35)
128 (112–143)
72 (63–82)
226 (25–579)
1.15 (0.90–1.58)
19 (14–24)
5 (0–37)
266 (64%)
90 (81–96)
1414 (860–1996)
109 (26%)

113 (31%)
72 (63–80)
33 (25–37)
214 (58%)
307 (83%)
88 (24%)
69 (19%)
143 (39%)
44 (12%)
141 (38%)
29 (25–34)
122 (109–138)
69 (62–77)
278 (129–558)
1.09 (0.89–1.40)
20 (15–25)
3 (0–19)
204 (55%)
0 (0-0)
1436 (840–2028)
96 (26%)

West African Ancestry
Pa

>80%
n = 309 (47%)

<5%
n = 353 (53%)

Pa

0.050
<.001
<.001
<.001
<.001
0.217
0.002
<.001
0.585
0.116
0.428
0.015
0.001
0.069
0.008
0.002
0.011
0.014
0.001
0.898
0.953

117 (38%)
63 (56–72)
30 (20–35)
102 (33%)
287 (93%)
65 (21%)
95 (31%)
61 (20%)
42 (14%)
142 (46%)
31 (26–34)
128 (112–144)
72 (63-82)
230 (85–564)
1.20 (0.91–1.60)
19 (14–24)
4 (0–36)
195 (63%)
93 (88–97)
1385 (856–1990)
80 (26%)

106 (30%)
72 (63–80)
34 (25–38)
211 (60%)
293 (83%)
85 (24%)
63 (18%)
135 (38%)
40 (11%)
137 (39%)
29 (25–34)
122 (108–138)
69 (62–77)
277 (128–558)
1.10 (0.88–1.40)
20 (15–25)
3 (0–19)
197 (56%)
0 (0-0)
1441 (844–2058)
88 (25%)

0.033
0.001
0.001
0.001
0.001
0.351
0.001
0.001
0.378
0.063
0.603
0.004
0.001
0.196
0.002
0.013
0.065
0.057
0.001
0.802
0.777

MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure risk score27; NT pro-BNP, N-terminal pro b-type natriuretic peptide.
NOTE. all of the p-values < 0.05 in the table need to be made boldface.
a
P values are for the comparison between self-identified Black vs White race or > 80% vs < 5% West African ancestry.
b
MAGGIC risk score was calculated without angiotensin inhibitors as input variables.
c
Angiotensin inhibitor exposure at baseline was the percentage of the target dose used in HFrEF clinical trials or the angiotensin inhibitors not tested in
HFrEF clinical trials, the percentage of the maximum daily dose used by the patient at study entry. (See Supplementary Table 1 for standardized dose
equivalents.)
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Fig. 1. Forest plot of adjusted association of time-varying exposure to angiotensin inhibitors with all-cause mortality in Cox proportional
hazards models stratified by self-identified race. All models were adjusted for angiotensin inhibitor propensity score, which was calculated
based on all baseline characteristics in Table 1. The x-axis is the hazard ratios and 95% confidence intervals plotted on a logarithmic scale.
The y-axes are the 3 different datasets stratified by self-identified race, GUIDE-IT, Guiding Evidence Based Therapy Using Biomarker
Intensified Treatment in Heart Failure trial; HFGR, Henry Ford Heart Failure Pharmacogenomic Registry; HFHS-EHR, retrospective analysis of electronic health records (EHR) & insurance claims data of HFrEF patients at Henry Ford Health System (who were not enrolled in
the HFGR).

analysis stratified by self-reported race. The point estimates for
the adjusted hazard ratios in White patients were lower than
those in Black patients in the HFGR (0.47 vs 0.65, respectively) and the HFHS-EHR datasets (0.49 vs 0.67, respectively). However, the 95% confidence intervals (CI) mostly
overlapped, so there was no significant difference between
the Black and White patients in those datasets (both interaction P values > 0.3). In the GUIDE-IT dataset, angiotensin
inhibitor exposure was significantly associated with more
survival benefit in the self-identified Black patients than in
White patients (interaction Pvalue = 0.045). The adjusted
hazard ratio (95% CI) was 0.26 (0.13–0.52); P < 0.001 in
the self-identified Black patients, and it was 0.75 (0.47–
1.21); P = 0.234 in the self-identified White patients. In the
random effects meta-analysis of the 3 datasets, the adjusted
hazard ratios (95% CI) were almost identical in the Black
and White patients: 0.52 (0.31–0.85) P= 0.006 and 0.54
(0.42–0.71) P= 0.001, respectively. To visualize these
results, survival curves for the association of time-varying angiotensin inhibitor exposure with all-cause mortality, stratified by self-identified race and high and low
angiotensin inhibitor exposure, were constructed from
the adjusted model data (Fig. 2). Consistent with the
above data, the survival curves largely overlapped
among self-identified Black and White patients with
HFrEF. The results were similar in the propensitymatched subgroups (Supplementary Material).

Association of Angiotensin Inhibitor Exposure With
Survival According to West African Ancestry

When comparing patients according to West African ancestry in the HFGR, the associations were similar to the comparisons according to self-identified race (Fig. 3). In patients with >
80% West African ancestry, the adjusted hazard ratio (95% CI)
was 0.66 (0.34–1.25; P = 0.200), and in patients with < 5%
West African ancestry, it was 0.56 (0.26–1.23; P= 0.147).
Again, the 95% confidence intervals mostly overlapped, so
there was not a significant difference in the association according to proportion of West African ancestry (interaction
Pvalue = 0.772). Survival curves stratified by proportion of
West African ancestry and high and low angiotensin inhibitor
exposure are displayed in Fig. 2B. These parallel the curves
stratified by self-identified race, such that patients with African
ancestry > 80% and those with < 5% had substantial overlap.
In almost all of the groups, the survival curves for high exposure
to angiotensin inhibitors are higher than those for low angiotensin inhibitor exposure, regardless of race or ancestry. The exception is the self-identified Black patients in the HFHS-EHR
dataset, in which the curves for high and low angiotensin inhibitor exposure are almost completely superimposed.
Discussion
To our knowledge, this is the first study to compare survival benefit associated with angiotensin inhibitors by both
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Fig. 2. Survival curves generated from adjusted Cox proportional hazards models for the association of time-varying angiotensin inhibitor
exposure with all-cause mortality in (A) HFGR stratified by self-identified race (Black: HR [95% CI] 0.65 [0.38–1.11] P = 0.112; White:
0.47 [0.21–1.04] P = 0.064). (B) HFGR stratified by proportion of West African ancestry (> 80% West African ancestry: 0.66 [0.34–1.25]
P= 0.200; < 5% West African ancestry: 0.56 [0.26–1.23] P = 0.147). (C) HFHS-EHR stratified by self-identified race (Black: 0.67 [0.30–
1.51] P = 0.337. White: 0.49 [0.20–0.92] P = 0.027). (D) GUIDE-IT stratified by self-identified race (Black: 0.26 [0.13–0.52] P < .001;
White: 0.75 [0.47–1.21] P = 0.234). All models were adjusted for angiotensin inhibitor propensity score, which was calculated based on all
baseline characteristics in Table 1. In (A), (B), and (C), Red lines are self-identified Black patients; blue lines are self-identified White
patients. In (D), the red lines indicate patients with > 80% West African ancestry, and the blue lines indicate patients with < 5% West African ancestry. High angiotensin inhibitor exposure was defined as the 3rd quartile of average angiotensin exposure over the course of followup (dashed lines), and low angiotensin inhibitor exposure was defined as the 1st quartile (solid lines). These plots are generated from the
adjusted Cox proportional hazards models, so it is important to note that they are solely for illustrative purposes of showing the adjusted
Cox proportional hazards model results, and they should not be interpreted as the more commonly used Kaplan-Meier plots. The nonsignificant interaction Pvalues (P> 0.1) in (A), (B) and (C) indicate that although there is separation of the curves visually, those differences were
not statistically significant. The interaction Pvalue in (D) (P = 0.045) indicates that angiotensin inhibitor exposure was associated with a significantly greater reduction in the risk for all-cause mortality in the patients who identified as Black in GUIDE-IT (data from the Guiding
Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure trial.28. HFGR, the Henry Ford Heart Failure Pharmacogenomic Registry27; HFHS-EHR, retrospective analysis of electronic health records (EHR) and insurance claims data of patients with
HFrEF at Henry Ford Health System (who were not enrolled in the HFGR).

self-identified race and genomic ancestry in patients with
HFrEF. Despite a significant racial disparity in the response
to angiotensin inhibitors for the treatment of hypertension,14
and previous data suggesting differential efficacy in regard
to hospitalization in HFrEF,12 we did not find a significant
racial disparity in survival benefit for the treatment of
HFrEF. The results of the ancestry-based analysis were similar to those of the race-based analysis. Previous studies
analyzed racial differences among the few hundred Black
patients enrolled in the landmark HFrEF clinical trials of
angiotensin inhibitors,7,12,13 but the findings were equivocal, and those trials were performed more than 20 years

ago. As a result, we sought out additional and more contemporary datasets with enrollment of a large proportion of
Black patients with HFrEF. The location of the Henry Ford
Health System in Detroit, Michigan, is uniquely advantageous for this research; nearly 80% of the population of
Detroit identifies as Black.35 However, in order to improve
the generalizability of our findings from this single center,
we sought out additional data from other locations. The
GUIDE-IT trial had much higher enrollment of patients
with HFrEF who identified as Black (40%) than most other
HFrEF landmark trials, and it included patients from 45
clinical sites across North America. Therefore, we were
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Fig. 3. Forest plot of adjusted association of time-varying exposure to angiotensin inhibitors with all-cause mortality in Cox proportional
hazards models in the HFGR stratified by self-identified race and proportion of West African genomic ancestry. All models were adjusted
for angiotensin inhibitor propensity score, which was calculated based on all baseline characteristics in Table 1. The x-axis shows the hazard
ratios and 95% confidence intervals plotted on a logarithmic scale. The y-axes are the HFGR stratified by self-identified race and proportion
of West African genomic ancestry. GUIDE-IT, data from the Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in
Heart Failure trial28; HFGR, the Henry Ford Heart Failure Pharmacogenomic Registry27; HFHS-EHR, retrospective analysis of electronic
health records (EHR) and insurance claims data of patients with HFrEF at Henry Ford Health System (who were not enrolled in the HFGR)

able to extend our findings from the 2 datasets at Henry
Ford Health System to a multicenter clinical trial.
Our findings contrast with certain previous observations,
but these data fit well when examined in full context and
may help to clarify what may otherwise seem inconsistent.
Noteworthy was a post hoc analysis of the Studies of Left
Ventricular Dysfunction (SOLVD) prevention and treatment trials by self-identified Black and White race by Exner
et al.12 They found a significant race interaction in HF hospitalization (adjusted HR [95% CI] for Black patients: 0.86
[0.64 1.16]; White patients: 0.51 [0.37 0.70]; Pvalue for
interaction = 0.005). However, when testing all-cause mortality, angiotensin inhibitor benefit was similar between
Black and White patients (adjusted HR for Black patients
0.85; White patients 0.92; Pvalue for interaction = 0.68).
Shekelle et al. performed a meta-analysis of Black and nonBlack patients in the SOLVD prevention and treatment trials and the SAVE trial.13 The outcome analyzed was mortality due to HF and, similar to our findings, benefit from
ACEIs did not differ by race (RR in Black patients: 0.89
[95% CI 0.74 1.06], and RR in White patients: 0.89 [95%
CI 0.82 0.97]). A subgroup analysis of the Black population in the Valsartan Heart Failure (Val-HeFT) trial,7 which
included 344 African American and South African patients,
found that the relative risk was 1.11 (95% CI 0.77–1.61) for
valsartan compared to placebo. In contrast, in the overall
trial, which was composed predominantly of White patients,
the relative risk for valsartan was 0.87 (95% CI 0.77–0.97).
Of note, the primary endpoint was a composite, including
death, cardiac arrest, hospitalization due to HF, or administration of intravenous inotropic or vasodilator drugs for 4
hours or more without hospitalization. Our group had previously performed a retrospective analysis of Black and

White patients by using older EHR data from HFHS (from
2000 to 2008).36 Similar to the present study, when the outcome was all-cause mortality alone, the hazard ratios for
angiotensin inhibitor benefit were almost identical in Black
and White patients (0.37 and 0.34, respectively). For hospitalization due to HF, the point estimate for the hazard ratio
in Black patients was lower when compared with that of
white patients (0.48 and 0.66, respectively), although these
differences did not reach statistical significance.
Taken together, when previous investigations focused on
mortality benefit, they appear to be consistent across race,
with which our current data agree. The contrasting data suggesting a difference in drug effect by race seems often
focused on other endpoints, particularly hospitalization. It
may be worth considering, given documented racial disparities in access to and quality of health care,37 that using hospitalization as the endpoint may be more susceptible to
confounding when trying to assess differences in drug efficacy by race.38 For example, hospitalizations due to HF are
229% and 240% higher for Black men and women compared to White men and women, respectively.39 Black
Americans use the emergency department for health care
significantly more than other racial groups.40 These different patterns in health care use by race make it more difficult
to draw conclusions regarding the impact of the medication
itself.
Another potential limitation of previous studies was categorizing patients by race alone and not also assessing genomic ancestry. That was by necessity because the previous
studies were conducted in the early 2000s, prior to the completion of the Human Genome Project and the wider availability of ancestry estimation. The recent and rapid increase
in the availability and affordability of genomic arrays
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should facilitate increased use of genomic ancestry in future
research. A common misconception is that race can be used
as a proxy for genetic ancestry, and this is especially problematic admixed populations.24 Race can reflect multiple
important factors, including genomic ancestry, socioeconomic status, cultural beliefs and practices, and local or
regional environmental exposures, making it a variable
with great associative power but poor resolution as to which
components are causative. In order to distinguish genetic
differences in drug outcomes from extrinsic determinants,
we evaluated differences by ancestry and self-reported race.
Indeed, Iniesta et al. found that differences in antihypertensive responses (including the ACEi lisinopril) were more
closely associated with genetically defined ancestry than
with self-defined ethnicity in admixed subjects.22 They also
found that a relatively small number of genetic variants
explained a large proportion of the difference in response to
the ARB candesartan in Black and White hypertensive
patients. Rao et al. compared outcomes of hypertensive
patients in the Systolic Pressure Interventional Trial
(SPRINT) by race and West African ancestry21 and, similar
to our study, they did not find significant differences by
West African ancestry. These findings and others suggest
that the use of genomic ancestry, in addition to race, may
be a better way of distinguishing pharmacological differences versus social determinants of health in precision medicine.24 While pointing out the potential value of genomics
in race-disparity research, it is also critically important to
identify and quantify the other factors contributing to race
associations, particularly the role of social determinants of
health in drug outcomes.23 Regardless of pharmacological
responses, social determinants of health can nullify beneficial drug outcomes. For example, if patients with HFrEF
are unable to obtain prescriptions, access pharmacies or
afford their medications, they will not benefit from any
drug therapy.3
It remains unclear why is there a significant racial disparity in the response to angiotensin inhibitors in hypertension/
blood pressure, yet this does not translate into HFrEF. In
addition to blood pressure lowering, angiotensin inhibitors
also have other beneficial effects in the treatment of HFrEF,
such as left ventricular remodeling, renal protection,
improved endothelial function, regulated sympathetic activity, and antiproliferative and antimigratory effects.41
Indeed, patients with HFrEF still experience improvement
in clinical outcomes resulting from angiotensin inhibitors
independent of their effects on blood pressure.42 Therefore,
it is possible that these other intermediate mechanisms,
rather than simply blood pressure lowering, provide clinical
outcome benefits in HFrEF and not in hypertension.

angiotensin inhibitors, and we adjusted for it as a covariate
in our models and in propensity-matched subgroup analysis.
Ideally, this analysis would be performed using data from
randomized clinical trials of angiotensin inhibitors but, as
previously stated, enrollment of Black patients in the landmark randomized clinical trials has been low. Moreover,
analyses of the landmark randomized clinical trials have
been limited to self-identified race. Another limitation is
that we did not assess specific social determinants of health
in our analysis because these data were not available in all
datasets. Our meta-analysis was not based on a systematic
review of prior trials but, rather, on the convenience of the
data available to us, which could be a source of bias.
Finally, the survival plots were not the more commonly
used Kaplan-Meier plots; rather, they were generated from
the adjusted Cox proportional hazards models. Therefore,
the survival plots are solely for illustrative purposes of the
results of the adjusted Cox proportional hazards models,
and they should not be interpreted as Kaplan-Meier plots.
Conclusions
In conclusion, we did not identify a significant racial disparity in survival benefit associated with angiotensin inhibitors in patients with HFrEF. Our findings were similar when
examining this in terms of proportion of West African genomic ancestry. These data support current HF guidelines and
may provide some reassurance concerning the benefits of
angiotensin inhibitor treatment in Black Americans.
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Limitations

Our study has some limitations. The datasets were observational as far as angiotensin inhibitor therapy. We
attempted to overcome the limitation of using observational
data by developing a propensity score for treatment by
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